Cargando…
Efficacy of botulinum toxin type A injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis
INTRODUCTION: Systemic sclerosis (SSc) is an autoimmune, connective tissue disorder of unknown etiology which causes vasculopathy and fibrosis. Raynaud’s phenomenon (RP) is a common complication of SSc, which leads to ischemia and gangrenes. Treatment of RP is a clinical problem and often remains in...
Autores principales: | Jokar, Mohammad Hassan, Baghbani, Bita, Geraylow, Kiarash Roustai, Shariati, Jaleh, Mehrad-Majd, Hassan, Mirfeizi, Zahra, Hashemzadeh, Kamila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847105/ https://www.ncbi.nlm.nih.gov/pubmed/36683833 http://dx.doi.org/10.5114/reum.2022.120757 |
Ejemplares similares
-
Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review
por: Żebryk, Paweł, et al.
Publicado: (2015) -
Use of Botulinum Toxin A to Treat Chemotherapy-Induced Raynaud’s Phenomenon
por: Potluri, Thrisha K, et al.
Publicado: (2021) -
Improvement of pterygium inversum unguis and Raynaud phenomenon with interdigital botulinum toxin injections
por: Kim, Daniel J., et al.
Publicado: (2022) -
Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review
por: Cai, Ruyi, et al.
Publicado: (2022) -
The Correlation between Helicobacter Pylori Infection and Disease Severity in Patients with Systemic Sclerosis
por: Atabati, Elham, et al.
Publicado: (2021)